Analysis of patients preferences in type 2 diabetes mellitus second-line drug treatment: A discrete choice experiment

This study highlights the importance of incorporating patient preferences into clinical decision-making. By quantifying preferences for second-line drug treatments, the study underscores the need for low-risk options that also consider weight change and intake conditions, aligning with the German National Health Care Guideline for T2D objectives for shared decision-making and treatment adherence. Recognizing individual sensitivities to risks and benefits is crucial for tailoring effective T2D treatment strategies. The study bridges clinical findings with patient perspectives, offering valuable insights into clinical practice, consideration for HTA processes, and design of clinical studies.

Authors

Institutions

Publication Details

Journal
PLoS ONE
Published
2025-09-15
DOI
https://doi.org/10.1371/journal.pone.0329743
Citations
2
Primary Topic
Diabetes Treatment and Management
Type
article
Field-Weighted Citation Impact
2.59
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Analysis of patients preferences in type 2 diabetes mellitus second-line drug treatment: A discrete choice experiment

Andrew Sadler, Axel Christian Mühlbacher, Ann-Kathrin Fischer, Elke Mathey
2 citations
PLoS ONE
Diabetes Treatment and Management
2.59
article

Analysis of patients preferences in type 2 diabetes mellitus second-line drug treatment: A discrete choice experiment

Andrew Sadler, Axel Christian Mühlbacher, Ann-Kathrin Fischer, Elke Mathey
article en
2 citations

Abstract

This study highlights the importance of incorporating patient preferences into clinical decision-making. By quantifying preferences for second-line drug treatments, the study underscores the need for low-risk options that also consider weight change and intake conditions, aligning with the German National Health Care Guideline for T2D objectives for shared decision-making and treatment adherence. Recognizing individual sensitivities to risks and benefits is crucial for tailoring effective T2D treatment strategies. The study bridges clinical findings with patient perspectives, offering valuable insights into clinical practice, consideration for HTA processes, and design of clinical studies.

PLoS ONEVol. 20(9)
Neubrandenburg University of Applied Sciences (DE), Novo Nordisk (Germany) (DE)
Openalex Percentile: Top 9%
Diabetes Treatment and Management
2.59
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Analysis of patients preferences in type 2 diabetes mellitus second-line drug treatment: A discrete choice experiment — Andrew Sadler, Axel Christian Mühlbacher, et al. · PLoS ONE (2025) | TGRS Research Map | TGRS